Dashi Pharmaceuticals

Dashi Pharmaceuticals is a preclinical-stage biotechnology company focused on the discovery and development of small molecule therapeutics for neurodegenerative diseases. The company specifically targets synucleinopathies, a group of disorders including Parkinson's disease and Multiple System Atrophy characterized by the abnormal aggregation of alpha-synuclein. Dashi's approach centers on identifying compounds that prevent the formation of toxic protein aggregates and promote the clearance of existing seeds. By addressing the fundamental molecular drivers of neurodegeneration, the company aims to develop disease-modifying therapies that slow or halt disease progression. Headquartered in San Francisco, Dashi leverages deep expertise in protein misfolding and structural biology to advance its internal pipeline.